EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage



Fabio Malavasi

Name of the laboratory

Laboratory of Immunogenetics
Dept of Genetics, Biology and Biochemistry
University of Torino Medical School
Via Santena, 19
10126 Torino

Members of the laboratory

Members: Laboratory of Immunogenetics
Unit Leader
Alberto Horenstein
Erika Ortolan
Tiziana Vaisitti
Ph.D. Student
Paola Bovino
Nicola Lo Buono
Giulia Nacci
Mariama Elbaroudi
Rossella Parrotta
Gianluca Zaccarello
Visiting Scientist
Alona Inzhutova
Semra Aydin
Rodica Markus
Francesca Cottino
Katiuscia Gizzi

Techniques available

  • Production of murine monoclonal antibodies
  • Production polyclonal antibodies
  • Production of human monoclonal antibodies
  • Purification of mAbs at a clinical grade

Publications (2019-present)

  • F. Morandi, D. Marimpietri, A. L. Horenstein, M. Bolzoni, D. Toscani, F. Costa, B. Castella, A. C. Faini, M. Massaia, V. Pistoia,N. Giuliani, and F. Malavasi. Microvesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NADC. OncoImmunology (2018, in press) (I.F. 7.719)
  • A. Chong, F. Malavasi, S. Israel, C. Chuen Khor, V. Bing Yap, M. Monakhov, S. Hong Chew, P. San Lai and R. P. Ebstein. ADP ribosyl-cyclases (CD38/CD157), social skills and friendship. Psychoneuroendocrinology 78: 185-192, 2017 (I.F. 4.704)
  • A. Chillemi, V. Quarona, L. Antonioli, D. Ferrari, A.L. Horenstein and F. Malavasi. Roles and modalities of ectonucleotidase in remodeling the multiple myeloma niche. Frontiers in Immunology 8: 305, 2017 (I.F. 5.695)
  • A.L. Horenstein, V. Quarona, F. Morandi, A. Chillemi and F. Malavasi. Adenosine in the bone marrow myeloma niche: immune checkpoint and key player in the progression of myeloma disease. Journal of Cell Signaling (2017, in press)
  • G. Mesiano, R. Zini, G. Montagner, N. Bianchi, R. Manfredini, A. Chillemi, M. Aglietta, G. Grignani, I. Lampronti, E. Fiorino, F. Malavasi, D. Sangiolo, R. Gambari and D. Ferrari. Analytic and dynamic secretory profile of patient-derived cytokine-induced killer cells. Molecular Medicine 9;23, 2017 (I.F. 3.530)
  • L. D’Abundo, E. Callegari, A. Bresin, A. Chillemi, B.K. Elamin, P. Guerriero, X. Huang, E. Saccenti, E.M.A.A. Hussein, F. Casciano, P. Secchiero, G. Zauli, G. A. Calin, G. Russo, L.J. Lee, C.M. Croce, G. Marcucci, S. Sabbioni, F. Malavasi and M. Negrini. Anti-leukemic activity of microRNA-26a in a chronic lymphocytic leukemia mouse model. Oncogene 36(47): 6617-6626, 2017 (I. F. 7.519)
  • I. Schiavoni, C. Scagnolari, A.L. Horenstein, P. Leone, A. Pierangeli, F. Malavasi, C. Ausiello and G. Fedele. CD38 modulates respiratory syncytial virus-driven pro-inflammatory processes in human monocyte-derived dendritic cells. Immunology (2017, in press) (I.F. 3.701)
  • W. Fumey, J. Koenigsdorf, V. Kunick, S. Menzel, K. Schütze, M. Unger, L. Schriewer, F. Haag, G. Adam, A. Oberle, M. Binder, R. Fliegert, A. Guse, YJ Zhao, H. Cheung Lee, F. Malavasi, F. Goldbaum, R. van Hegelsom, C. Stortelers, P. Bannas, F. Koch-Nolte. Nanobodies effectively modulate the enzymatic activity of CD38 and allow specific imaging of CD38+ tumors in mouse models in vivo. Scientific Report 7(1):14289, 2017
  • Marshall D., Chillemi A., Malavasi F. and Prudent J. Precision Targeting of Ion Channel Blocker for the Treatment of AML. Blood 130: 5203, 2017 (I.F. 13.164)
  • F. Morandi, A. L. Horenstein, R. Rizzo and F. Malavasi. The Role of Extracellular Adenosine Generation in the Development of Autoimmune Diseases Mediators of Inflammation
  • N.W.C.J. van de Donk, P.G. Richardson and F. Malavasi. CD38 antibodies in multiple myeloma: back to the future. Blood (2017, in press) (I.F. 13.164)
  • M. Gregori, A. Orlando. F. Re, S. Sesana, L. Nardo, D. Salerno, F. Mantegazza, E. Salvati, A. Zito, F. Malavasi, M. Masserini and E. Cazzaniga. Novel anti-transferrin receptor antibodies improve the blood-brain barrier crossing efficacy of immunoliposomes. Journal of Pharmaceutical Sciences 105 (1): 276-283, 2016 (I.F. 2.590)
  • N.W.C.J.van de Donk, P. Moreau, T. Plesner, A. Palumbo, F. Gay, J.P. Laubach, F. Malavasi, H.Avet-Loiseau, M.V. Mateos, P. Sonneveld, H.M. Lokhorst, P. G. Richardson. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma. Blood 127: 681-695, 2016 (I.F. 13.164)
  • A. Zito, C. Bromuro, G. Mandili, P. Chiani, A.L. Horenstein, F. Malavasi, R. Cauda, A. Cassone and A. Torosantucci. A murine, bispecific monoclonal antobody simultaneously recognizing β-glucan and MP65 determinants in candida species. PLOS One 11(2): e 0148714, 2016 (I.F. 3.234)
  • D. J. Marshall, S. Harried, J. Murphy, C. Hall, M. S. Shekhani, C. Pain, C. Lyons, A. Chillemi, F. Malavasi, H. L. Pearce, J. S. Thorson and J. R. Prudent. Extracellular antibody drug conjugates exploiting the proximity of two proteins. Molecular Therapy 24(10): 1760-1770, 2016 (I.F. 6.225)
  • L. Antonioli, C. Blandizzi, F. Malavasi, D. Ferrari and G. Haskό. Anti-CD73 immunotherapy: a viable way for reprogramming the tumor microenvironment. Oncoimmunology Vol. 5, NO 9, e1216292 (3 pages), 2016 (I.F. 7.644)
  • A.L. Horenstein, V. Quarona, D. Toscani, F. Costa, A. Chillemi, V. Pistoia, N. Giuliani and F. Malavasi. Adenosine generated in the bone marrow niche through a CD38-mediated pathway correlates with progression of human myeloma. Molecular Medicine 13: 22, 2016 (I.F. 3.53)
  • A.L. Horenstein, A. Chillemi, V. Quarona, A. Zito, V. Mariani, A. C. Faini, F. Morandi, I. Roato, C. Ausiello and F. Malavasi. Antibody mimicry, receptors and clinical applications. Human Antibodies, 2016
  • D. Ferrari, F. Malavasi and L. Antonioli. A purinergic Trail for metastases. Trends in Pharmacological Sciences 38(3): 277-290, 2016 (I.F. 11.840)
  • M. Benkisser-Petersen, M. Buchner, A. Dörffel, M. Dühren-von-Minden, R. Claus, K. Kläsener, K. Leberecht, M. Burger, C. Dierks, H. Jumaa, F. Malavasi, M. Reth, H. Veelken, J. Duyster, K. Zirlik. Spleen tyrosine kinase involved in the CD38 signal transduction pathway in chronic lymphocytic leukemia. PLOS One 11(12): e0169159, 2016 (I.F. 3.057)
  • F. Malavasi, A. Chillemi, B. Castella, I. Schiavoni, D. Incarnato, S. Oliva & A.L. Horenstein. CD38 and antibody therapy: what can basic science add?. Blood 128: SCI-36, 2016 [abstract]
  • V. Quarona, V. Ferri, A. Chillemi, M. Bolzoni, C. Mancini, G. Zaccarello, I. Roato, F. Morandi, D. Marimpietri, G. Faccani, E. Martella, V. Pistoia, N. Giuliani, A. L. Horenstein and F. Malavasi. Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche. Annals of the New York Academy of Sciences 1335: 10-22, 2015 (I.F. 4.039)
  • F. Morandi, B. Morandi, A.L. Horenstein, A. Chillemi, V. Quarona, G. Zaccarello, P. Carrega, V. Pistoia and F. Malavasi. A non-canonical adenosinergic pathway led by CD38 in human melanoma cells induces suppression of T cell proliferation. Oncotarget 6 (28): 25602-18, 2015 (I.F.6.627)
  • F. Morandi, A. L. Horenstein, A. Chillemi, V. Quarona, S. Chiesa, A. Imperatori, S. Zanellato, L. Mortara, M. Gattorno, V. Pistoia and F. Malavasi. CD56bright CD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation1. Journal of Immunology 195: 965-972, 2015 (I.F. 5.362)
  • G. Fedele, I. Sanseverino, K. D’Agostino, I. Schiavoni, C. Locht, A. L. Horenstein, F. Malavasi and C. Ausiello. Unconventional adenosine-producing suppressor T cells induced by dendritic cells exposed to BPZE1 pertussis vaccine. Journal of Leukocyte Biology 98 (4): 631-639, 2015 (I.F. 4.304)
  • A.L. Horenstein, A. Chillemi, V. Quarona, A. Zito, I. Roato, F. Morandi, D. Marimpietri, M. Bolzoni, D. Toscani, R. Oldham, M. Cuccioloni, A. K. Sasser, V. Pistoia, N. Giuliani and F. Malavasi. NAD+-metabolizing ectoenzymes in remodeling tumor-host interactions: the human myeloma model. Cells 4 (3): 520-537, 2015
  • T. A. Karakasheva, T. J. Waldron, E. Eruslanov, J.S. Lee, S. O’Brien, P. D. Hicks, D. Basu, S. Singhal, F. Malavasi, and A. K. Rustgi. CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer. Cancer Research 75 (19): 4074-4085, 2015 (I.F. 9.329)
  • P. Engel, L. Boumsel, R. Balderas, A. Bensussan, V. Gattei, V. Horejsi, B.Q. Jin, F. Malavasi, F. Mortari, H. Stockinger, M.C. van Zelm, H. Zola and G. Clark. Nomenclature of CD molecules. Journal of Immunology 195 (10): 4555-4563, 2015 (I.F. 4.922)
  • N. Lo Buono, S. Morone, A. Giacomino, R. Parrotta, E. Ferrero, F. Malavasi, E. Ortolan and A. Funaro. CD157 at the intersection between leukocyte trafficking and epithelial ovarian cancer invasion. Frontiers in Bioscence 19: 366-78, 2014 (I.F. 4.249)
  • E. M. Ferrero, N. Lo Buono, A. Horenstein, A. Funaro and F. Malavasi. The ADP-ribosyl cyclases – the current evolutionary state of the ARCs. Frontiers in Bioscience 19:986-1002, 2014 (I.F.4.249)
  • R. Rizzo, V. Audrito, P. Vacca, D. Rossi, D. Brusa, M. Stignani, D. Bortolotti, G. D' Arena, M. Coscia, L. Laurenti, F. Forconi, G. Gaidano, MC Mingari, L. Moretta, F. Malavasi and S. Deaglio. HLA-G is a component of the CLL escape repertoire to generate immune suppression: impact of HLA-G 14 bp polymorphism. Haematologica 99:888-896, 2014 (I.F.5.868).
  • G. Fedele, M. Di Girolamo, U. Recine, R. Palazzo, F. Urbani, A. L. Horenstein, F. Malavasi and C. Ausiello. CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of pro-tumorigenic IL-6 and impaired secretion of IFN-gamma cytokines and proliferation.Mediators of Inflammation 2013: 7, 2014 (I.F.2.417)
  • A. Chillemi, G. Zaccarello, V. Quarona, M. Lazzaretti, E. Martella, N. Giuliani, R. Ferracini, V. Pistoia, A. L. Horenstein and F. Malavasi. CD38 and bone marrow microenvironment. Frontiers in Bioscience 19: 152-62, 2014 (I.F. 4.249)
  • O. Trubiani, A.L. Horenstein, F. Caciagli, S. Caputi, F. Malavasi and P. Ballerini. Expression of P2X7 ATP receptor mediating the IL8 and CCL20 release in human periodontal ligament stem cells. Journal of Cellular Biochemistry 115 (6): 1138-1146, 2014 (I.F.3.368)
  • J. Congleton, M. Shen, R. MacDonald, F. Malavasi and A. Yen. Phosphorylation of c-Cbl and p85 PI3K driven by All-Trans Retinoic Acid (ATRA) and CD38 depends on Lyn Kinase Activity. Cellular Signalling 26 (7): 1589-1597, 2014 (I.F.4.471)
  • S. Chung, Y. L. Lin, C. Reed, C. Ng, Z. J. Cheng, F. Malavasi, J. Yang, V. Quarmby and A. Song. Characterization of in vitro antibody-dependent cell-mediated cytotoxicity activity of therapeutic antibodies-impact of effector cells. Journal of Immunological Methods 407: 63-75, 2014 (I.F.2.005)
  • A. Pezzolo, D. Marimpietri, L. Raffaghello, C. Cocco, A. Pistorio, C. Gambini, M. Cilli, A.L. Horenstein, F. Malavasi and V. Pistoia. Failure of anti tumor-derived endothelial cell immunotherapy depends on augmentation of tumor hypoxia. Oncotarget 5 (21): 10368-10381, 2014 (I.F.6.627)
  • T. Vaisitti, S. Serra, C. Pepper, D. Rossi, L. Laurenti, G. Gaidano, F. Malavasi, S. Deaglio. CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic lymphocytic leukemia cells. Leukemia 27 (5): 1177-1181, 2013 (IF 8.296)
  • D. Brusa, S. Serra, M. Coscia, D. Rossi, G. D'Arena, L. Laurenti, O. Jaksic, G. Fedele, G. Inghirami, G. Gaidano, F. Malavasi and S. Deaglio. The PD-1/PD-L1 axis contributes to T cell dysfunction in chronic lymphocytic leukemia. Haematologica 98(6):953-63, 2013 (IF 5.935)
  • V. Audrito, T. Vaisitti, S. Serra, C. Bologna, D. Brusa, F. Malavasi and S. Deaglio. Targeting the microenvironment in chronic lymphocytic leukemia offers novel therapeutic options. Cancer Letters 328: 27-35, 2013 (IF 4.258)
  • E. J. Pavón , E. Zumaquero , A. Rosal-Vela , KM. Khoo, D. Cerezo-Wallis, S. García-Rodríguez, M. Carrascal, J. Abián, R. Graeff, J.L. Callejas-Rubio, N. Ortego-Centeno, F. Malavasi, M. Zubiaur and J. Sancho. Increased CD38 expression in T cells and circulating anti-CD38 IgG autoantibodies differentially correlate with distinct cytokine profiles and disease activity in systemic lupus erythematosus patients. Cytokine 62 (2): 232-243, 2013 (IF 2.518)
  • V. Quarona, G. Zaccarello, A. Chillemi, E. Brunetti, VK. Singh, E. Ferrero, A. Funaro A, AL. Horenstein, F. Malavasi. CD38 and CD157: A long journey from activation markers to multifunctional molecules. Clinical Cytometry 84:207-217, 2013 (I.F. 2.283)
  • A. Chillemi, G. Zaccarello, V. Quarona, M. Ferracin, C. Ghimenti, M. Massaia, A. L. Horenstein and F. Malavasi. Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule. Molecular Medicine 19: 99-108, 2013 (I.F. 4.469)
  • M. Cecati, M. Emanuelli, S.R. Giannubilo, V. Quarona, F. Malavasi, A.L. Tranquilli, and F. Saccucci. Contribution of adenosine-producing ectoenzymes to the mechanisms underlying the mitigation of maternal-fetal conflicts. Journal of Biological Regulators & Homeostatic Agents 27(2):519-529, 2013 (I.F. 5.183)
  • A. L. Horenstein, A. Chillemi, G. Zaccarello, S. Bruzzone, V. Quarona, A. Zito, S. Serra and F. Malavasi. A CD38/CD203a/CD73 ectoenzymatic pathway independent from CD39 runs a novel adenosinergic loop in human T lymphocytes. OncoImmunology 9: e26246, 2013 (I.F. 6.283)